tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mason Carrico, 41 are a BUY (91.11%), 4 are a HOLD (8.89%).
Analyst Mason Carrico, currently employed at STEPHENS, carries an average stock price target met ratio of 42.36% that have a potential upside of 13.21% achieved within 105 days.
Mason Carrico’s has documented 89 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TXG, 10X Genomics at 10-Oct-2024.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 5/24/2022. The price target of $25 was fulfilled within 16 days with a profit of $5.31 (26.97%) receiving and performance score of 16.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$42
$8.85 (26.70%)
$35
10 days ago
(29-Oct-2024)
1/6 (16.67%)
$8.22 (24.33%)
70
Buy
$40
$6.85 (20.66%)
$37
25 days ago
(14-Oct-2024)
4/10 (40%)
$5.74 (16.75%)
132
Buy
$37
$3.85 (11.61%)
$41
3 months 2 days ago
(06-Aug-2024)
0/4 (0%)
$12.1 (48.59%)
Buy
$28
$-5.15 (-15.54%)
$37
8 months 7 days ago
(01-Mar-2024)
3/5 (60%)
$8.06 (40.42%)
73
Buy
$32
$-1.15 (-3.47%)
$32
1 years 4 months 1 days ago
(07-Jul-2023)
2/5 (40%)
$11.7 (57.64%)
481
Which stock is Mason Carrico is most bullish on?
Which stock is Mason Carrico is most reserved on?
What Year was the first public recommendation made by Mason Carrico?
